Andarine

First-generation SARM. Partial agonist at the androgen receptor — this partial agonism may explain both its anabolic effects and its vision side effects. The vision side effect is attributed to binding to androgen receptors in the eye — specifically the retina — causing the distinctive yellow tint.

Non-steroidal oral compound. Short half-life of 3-4 hours requires multiple daily doses for stable levels.

Andarine was an early-generation SARM that attracted attention for producing lean hard muscle with strength increases and a dry appearance. Its development was discontinued specifically because of vision side effects in human volunteers, which reduced its adoption relative to later SARMs. In performance use it appears in cutting phases and recomposition protocols among users who are specifically familiar with the vision side effect and choose to manage it by limiting dose and duration. The physique effects it produces are real but the compound has been largely superseded by later SARMs that do not carry the vision risk.

Andarine has limited stacking use in current performance settings because its development was discontinued and later SARMs offer comparable effects without the vision risk. When it does appear in stacks it functions similarly to Masteron or Stanozolol in terms of its role, adding hardness and a dry visual effect to an existing base. It is sometimes combined with Ostarine in mild cutting stacks among users who are specifically familiar with both compounds and want to keep the combined androgenic load low.

• Development discontinued — no approved use
• Investigated for osteoporosis and muscle wasting before discontinuation

• Vision disturbances — yellow tint, difficulty in low-light — dose-dependent and reversible
• Testosterone suppression
• Androgenic effects at higher doses
• HDL suppression
• Short half-life means more frequent dosing increases cumulative exposure

The vision disturbance that Andarine causes is not a rare or individual reaction. It is a class effect related to androgen receptor binding in the retina. It presents as a yellow tint to vision and difficulty adjusting to low light, particularly when moving from bright to dark environments. While these effects are dose-dependent and reverse after stopping, they can be significant and disorienting during use. The short half-life of three to four hours requires multiple daily doses to maintain stable levels, which increases the cumulative daily androgen receptor exposure in ocular tissue.

Approximately 2-3 weeks detection window.